For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease ...

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

An experimental cancer vaccine has shown promising results in keeping pancreatic and colorectal cancers from coming back. In ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

KRAS has always been a natural enemy for drug hunters to pursue. Mutated forms of the protein and its family members NRAS and HRAS are found in some 30% of human cancers.